Diagnostic Approach for Pancreatic Cancer

Initial Diagnostic Approach

The European Society for Medical Oncology recommends contrast-enhanced multi-detector computed tomography (MD-CT) with pancreatic protocol as the preferred initial imaging modality for detection and staging of pancreatic cancer, allowing assessment of the primary tumor location and size, vascular invasion, and evaluation of metastases to liver, lymph nodes, and peritoneum 2, 3, 4
MD-CT provides information on the primary tumor and metastases, and is used in conjunction with other imaging modalities such as MRI with magnetic resonance cholangiopancreatography (MRCP) to better distinguish solid from cystic masses 4, 3

The American Gastroenterological Association recommends EUS-guided biopsy over percutaneous sampling due to lower risk of tumor seeding, with EUS-FNA being the most accurate method for obtaining tissue diagnosis 3

Histological proof of malignancy is mandatory in unresectable cases or when neoadjuvant therapy is planned, according to the National Comprehensive Cancer Network 1, 3
Biopsy should be restricted to cases where imaging results are ambiguous, and for patients who will undergo surgery with radical intent, a previous biopsy is not obligatory 3

The European Society for Medical Oncology states that positron emission tomography (PET) has no established role in primary diagnosis as it cannot reliably differentiate between chronic pancreatitis and pancreatic cancer 3
Tumor markers such as CA19.9 have limited diagnostic value due to lack of specificity and false negatives in patients lacking the Lewis antigen 4, 3

Percutaneous biopsy of potentially resectable tumors should be avoided due to risk of peritoneal seeding, as recommended by the American College of Radiology 3

The American Cancer Society recommends regular EUS and MRI for early detection in high-risk populations, including individuals with hereditary conditions and patients with recent-onset diabetes mellitus 6